Disease-Modifying Therapy
Tolebrutinib particularly beneficial in patients with MS who have more MRI lesions
WEST PALM BEACH, Fla. — Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show.
Risks of ending disease-modifying therapy may be ‘minimal’ in older, stable adults with MS
WEST PALM BEACH, Fla. — It may be sensible for older patients with MS who have prolonged stability to cease disease-modifying therapy, but more data are needed to understand the effects of discontinuation in this group, an expert said.
Comorbidities linked to early discontinuation of disease-modifying therapy trials for MS
WEST PALM BEACH, Fla. — A higher comorbidity burden was linked to an increased rate of adverse events as well as early discontinuation among patients with MS who participated in phase 3 clinical trials of disease-modifying therapies, data show.
Most patients with sickle cell disease not prescribed disease-modifying therapy
The underutilization of disease-modifying therapy by people with sickle cell disease is “persistent and alarming,” according to an analysis of real-world data.
TNF inhibitors may reduce fracture risk 29% vs NSAIDs in axial spondyloarthritis
TNF inhibitors for the treatment of axial spondyloarthritis may decrease the risk for hip or spine fracture by as much as 29% compared with NSAIDs, according to data published in Arthritis & Rheumatology.
Cycling JAKi after poor response in rheumatoid arthritis better than switching to bDMARD
For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying antirheumatic drug, according to data.
TNF inhibitors do not increase adverse event risk in rheumatoid arthritis-associated ILD
Treatment with TNF inhibitors yielded no differences in outcomes vs. other antirheumatic therapies among U.S. veterans with rheumatoid arthritis-associated interstitial lung disease, according to data published in The Lancet Rheumatology.
Odds of DMARD-free remission in rheumatoid arthritis may depend on biological DMARD use
Although sustained remission free of disease-modifying antirheumatic drugs “does not seem attainable” for patients with rheumatoid arthritis requiring biological DMARDs, it is possible for those who do not require them, according to data.
EULAR: Start inflammatory arthritis therapies ‘without delay’ after cancer remission
Targeted therapies for active inflammatory arthritis should be started “without delay” for patients with cancer in remission, according to new EULAR points to consider published in Annals of the Rheumatic Diseases.
Public insurance leads to faster bDMARD initiation in juvenile idiopathic arthritis
WASHINGTON — Patients with juvenile idiopathic arthritis receive biologic disease-modifying antirheumatic drugs significantly sooner on public insurance vs. private, particularly if they have oligoarticular JIA, according to a speaker.